Successful treatment of Ophionyssus natricis with afoxolaner in two Burmese pythons (Python molurus bivittatus).

The efficacy of afoxolaner was evaluated in two captive Burmese python snakes, which were naturally infested with Ophionyssus natricis mites. The administration of a single oral dose of afoxolaner eliminated live O. natricis mites from both snakes by Day 3. Environmental samples collected from the snakes' terrariums were negative for dead mites by Day 30.

L'efficacité de l'afoxolaner a été évaluée chez deux serpents python birmans captifs, naturellement infestés par des acariens Ophionyssus natricis. L'administration d'une dose orale unique d'afoxolaner a éliminé les acariens O. natricis vivants des deux serpents à jour 3. Les échantillons environnementaux prélevés dans les terrariums des serpents étaient négatifs pour les acariens morts à jour 30.

Se evaluó la eficacia de afoxolaner en dos serpientes pitón birmanas cautivas, que estaban naturalmente infestadas con ácaros Ophionyssus natricis. La administración de una sola dosis oral de afoxolaner eliminó los ácaros O. natricis vivos de ambas serpientes en el día 3. Las muestras ambientales recolectadas de los terrarios de las serpientes dieron negativo para ácaros muertos en el día 30.

A eficácia do afoxolaner foi avaliada em duas cobras python birmanesas de cativeiro, que foram naturalmente infestadas com ácaros Ophionyssus natricis. A administração de uma única dose oral de afoxolaner eliminou ácaros O. natricis vivos de ambas as cobras no dia 3. As amostras ambientais coletadas dos terrários das cobras foram negativas para ácaros mortos no dia 30.

Efficacy of afoxolaner plus milbemycin oxime and afoxolaner alone as treatment for sarcoptic mange in naturally infested dogs.

Sarcoptic mange is a pruritic, contagious, ectoparasitic skin disease that affects mammals, including the domestic dog. The objective of this study was to evaluate and compare the efficacy of afoxolaner plus milbemycin oxime (NexGard Spectra) and afoxolaner alone (NexGard) as treatments for sarcoptic mange in naturally infested dogs. A total of 142 dogs naturally infested with Sarcoptes scabiei was evaluated. The dogs were diagnosed by microscopic examinations of skin scrapings. The dogs were divided into 2 groups: 96 dogs were treated with a combined dosage of 2.50 to 5.36 mg/kg body weight (BW) of afoxolaner and 0.50 to 1.07 mg/kg BW of milbemycin oxime and 46 dogs were treated with 2.50 mg/kg BW of afoxolaner alone. The presence or absence of pruritus and lesions were evaluated using an analogous scale on days 7, 14, 21, 28, and 56 after receiving the treatment. Data obtained were analyzed by Student's t-test (P ≤ 0.05). The single oral treatment of afoxolaner plus milbemycin oxime resulted in a significant reduction in pruritus of 87.4% at 28 d after treatment (P ≤ 0.05). Resolution of the lesions after treatment was variable, with a significant decrease (P ≤ 0.05) observed within the first 14 d, although this parameter continued to improve until the end of the study on day 28, when a decrease of 96% was observed. By the end of the study, a single dose of either the afoxolaner alone or the afoxolaner combined with milbemycin oxime was effective in significantly reducing the signs associated with sarcoptic mange during a 56-day evaluation period.

La gale sarcoptique est une maladie cutanée pruritique et contagieuse causée par un ectoparasite qui affecte les mammifères, incluant le chien domestique. L'objectif de la présente étude était d'évaluer et de comparer l'efficacité d'afoxolaner plus oxime de milbemycine (NexGard Spectra) et l'afoxolaner seul (NexGard) comme traitement pour la gale sarcoptique chez des chiens naturellement infestés. Un total de 142 chiens naturellement infestés avec Sarcoptes scabei furent évalués. Les chiens étaient diagnostiqués par examen microscopique de grattages cutanés. Les chiens furent divisés en deux groupes : 96 chiens furent traités avec un dosage combiné de 2,50 à 5,36 mg/kg de poids corporel (BW) d'afoxolaner et de 0,50 à 1,07 mg/kg BW d'oxime de milbemycine et 46 chiens furent traités avec 2,50 mg/kg BW d'afoxolaner seul. La présence ou l'absence de prurit et de lésions furent évaluées en utilisant une échelle analogue aux jours 7, 14 21, 28 et 56 après avoir reçu le traitement. Les données obtenues furent analysées à l'aide d'un test de t de Student (P ≤ 0,05). Le traitement unique avec de l'afloxolaner plus oxime de milbemycine a résulté en une réduction significative du prurit de 87,4 % au jour 28 après le traitement (P ≤ 0,05). Une résolution des lésions après le traitement était variable, avec une diminution significative (P ≤ 0,05) étant observée au cours des 14 premiers jours, bien que ce paramètre continua de s'améliorer jusqu'à la fin de l'étude au jour 28, alors qu'une diminution de 96 % fut observée. À la fin de cette étude, une dose unique de soit de l'afoxolaner seul ou une combinaison afoxolaner-oxime de milbemycie était efficace à réduire de manière significative les signes associés avec la galle sarcoptique durant une période d'évaluation de 56 jours.(Traduit par Docteur Serge Messier).

Evaluation of the effect of afoxalaner with milbemycin 1 oxime in the treatment of rabbits naturally infected with Psoroptes cuniculi.

Rabbits (Oryctolagus cuniculi) are very popular as pets. However, problems of otitits caused by Psoroptes cuniculi are one of the main reasons to visit the veterinarian. Isoxazolines are an alternative treatment to treat this mite, and therefore, an evaluation of the effectiveness of oral afoxalaner with milbemycin oxime in rabbits infected with P. cuniculi was carried out. Nineteen rabbits, of New Zealand breed, with otitis due to an infection with P. cuniculi, were treated, whereas six rabbits were left untreated and formed the control group. The ear canals of each individual were examined, through the collection of otic exudate samples with cotton swabs. These were visualized under the microscope to identify the ectoparasite. Each animal was treated with a single oral dose of 2.50 mg / kg of afoxolaner, and 0.50 mg / kg of milbemycin oxime. Clinical signs and lesions associated with the infection, such as the presence of detritus, cerumen and / or scabs, and erythema, were evaluated. After receiving the treatment, all the lesions were classified as: mild, moderate and intense, with a visual analog scale. A week after providing medication, there was a decrease in the lesions of the group treated with Nexgard Spectra®, without further topical or systemic treatment. The decrease was gradual in the treated group and no recurrence was detected of P. cuniculi infection in both ears. Thus, the administration of a single oral dose of afoxolaner with milbemycin oxime was effective for the treatment of P. cuniculi infection in rabbits.

Use of afoxolaner for the treatment of lice (Goniodes pavonis) in different genera (Chrysolophus spp, Lophura spp, Phasianus spp, and Syrmaticus spp) and species of pheasants and West Mexican Chachalacas (Ortalis poliocephala).

Lice are ectoparasites capable of affecting birds, and can result in direct and indirect damage to their host. Afoxolaner is an isoxazoline that has been shown to be effective against these ectoparasites without known adverse effects. The objective of this research was to evaluate the effect of afoxolaner on lice in pheasants and plain chachalacas. A total of 29 pheasants of different genera and species (Chrysolophus pictus, C. amherstiae, Lophura swinghoii, L. nycthemera, Phasianus colchicus, and Syrmaticus reevesii) and 18 West Mexican Chachalacas (Ortalis poliocephala) naturally infested with Goniodes pavonis were used. The birds were allocated to one of two groups: group 1 treated with 2.50 mg/kg of afoxolaner, and group 2 given no treatment. Ectoparasites were collected using the adhesive tape technique and identified. Afoxolaner was administered later as a single dose to group 1, and the clinical assessment to detect ectoparasites was repeated 28 days post-treatment. On day 28 post-treatment, group 1 was found to be negative for the presence of lice. The body weights were compared at the beginning and end of the clinical assessment in both groups and a significant difference in weight of treated birds was found. The mean body weight decreased by 0.017 g in control group, whereas it increased by 0.016 g in treated group. Oral administration of afoxolaner is an effective option for the treatment of Goniodes pavonis infestations in zoo birds.

Effect of oral afoxolaner on naturally occurring infestations of peacocks by the louse Goniodes pavonis.

BACKGROUND: Ectoparasitism of ornamental birds, including captive species kept in zoos, represents a serious health problem. Up to 13 different species of lice have been reported to affect peacocks worldwide and heavy infestation may cause anaemia. Because of this, alternatives to the prevailing treatments have been sought including use of isoxazolines. This class of drugs has been used successfully in poultry without adverse effects on health or production. OBJECTIVE: To evaluate the effect of afoxolaner on the peacock louse (Goniodes pavonis). ANIMALS: Twenty-three peacocks (Pavo cristatus) with naturally occurring infestation with G. pavonis. METHODS AND MATERIALS: The peacocks were divided in two groups; one was treated once orally with 2.5 mg/kg afoxolaner and the other group received no treatment. Samples were collected using the acetate tape technique, for identification of lice by microscopy. Concomitantly, blood samples were taken to evaluate the haematocrit before and after the intervention. RESULTS: Treatment with afoxolaner significantly decreased the number of peacocks positive for lice (P = 0.02) compared to the control group, in which the number of positive birds did not decrease. The haematocrit improved in the afoxolaner-treated group from a baseline of 46.4%-54.7% at 35 days post-treatment, whereas it decreased in untreated birds (44.6%-40.7%). No adverse effects attributed to afoxolaner treatment were observed. CONCLUSIONS AND CLINICAL IMPORTANCE: Oral administration of afoxolaner is an effective treatment for G. pavonis infestation of peacocks.

Efficacy of two anthelmintic treatments, spinosad/milbemycin oxime and ivermectin/praziquantel in dogs with natural Toxocara spp. infection.

Toxocara canis is one of the most important zoonotic parasites of dogs. The aim of the present study was to compare the efficacy of spinosad/milbemycin oxime and ivermectin/praziquantel in dogs naturally infected with Toxocara spp. We studied 200 dogs with a positive diagnosis of Toxocara spp. Through coproparasitoscopic analysis, two study groups of 100 dogs each were assigned: spinosad/milbemycin oxime at a dose of 30-60mg/kg and 0.75-1.0mg/kg, respectively, or ivermectin/praziquantel administered at a dose of 0.2mg/kg and 5mg/kg, respectively. Both groups received a single dose. Three stool samples, one at day 0 before treatment, and at 14 and 28days post-treatment were examined using concentration-flotation techniques. In both treatments, the number of Toxocara spp. eggs decreased; with spinosad/milbemycin oxime treatment, eggs decreased by 87% at 14days (P=0.008) and 94% at 28days after treatment, compared with 71% at day 14 and 88% at day 28 in dogs medicated with ivermectin/praziquantel. The spinosad/milbemycin oxime treated group showed a greater decrease in the number of Toxocara spp. positive dogs compared to the group receiving ivermectin/praziquantel.